|
|
|
|
|
|
Sponsored by: |
Psychiatric University Hospital, Zurich |
Information provided by: | Psychiatric University Hospital, Zurich |
ClinicalTrials.gov Identifier: | NCT00750217 |
Buprenorphine is an important alternative to methadone in the maintenance treatment of heroin addiction. Transfer from methadone to buprenorphine requires a reduction of daily methadone dosage below 30 mg to avoid withdrawal after the first buprenorphine intake. The study hypothesis states that the transfer from a daily methadone dosage between 60 mg and 100 mg to buprenorphine can be carried out without withdrawal using buprenorphine patches (35 micro grams per hour) within 12 to 48 hours after last methadone intake.
Condition | Intervention | Phase |
Heroin Addiction |
Drug: Buprenorphine patch and sublingual tablets |
Phase IV |
MedlinePlus related topics: | Heroin |
ChemIDplus related topics: | Methadone Methadone hydrochloride Buprenorphine Buprenorphine hydrochloride Diacetylmorphine Diacetylmorphine hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone. |
Estimated Enrollment: | 10 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.
Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake.
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Switzerland | |||||
Psychiatric University Hospital | Recruiting | ||||
Zurich, Switzerland, 8032 | |||||
Contact: Melanie Hess, med. pract. 0041 44 384 21 11 melanie.hess@puk.zh.ch | |||||
Contact: Rudolf Stohler, MD 0041 44 205 58 00 rudolf.stohler@puk.zh.ch | |||||
Principal Investigator: Melanie Hess, med. pract. |
Psychiatric University Hospital, Zurich |
Study Director: | Rudolf Stohler, MD | Psychiatric University Hospital |
Study Chair: | Lukas Boesch, PhD | Psychiatirc University Hospital |
Responsible Party: | Psychiatric University Hospital, Zurich ( Stohler Rudolf MD ) |
Study ID Numbers: | E-54/2007 |
First Received: | September 9, 2008 |
Last Updated: | September 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00750217 |
Health Authority: | Switzerland: Swissmedic |
|
|
|
|
|